Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
O'Keefe Stevens Advisory, Inc Dominick D'Angelo | “Perrigo was our biggest loser in 2025 at -46%, and the pain continued into Q1. On February 26, Perrigo reported Q4 2025 results, missed EPS, recorded a $1.3 billion goodwill impairment, and guided 202” | BULL | Q1 2026 Apr 24, 2026 | View Pitch |
Meridian Contrarian Fund ArrowMark Partners | “Perrigo Company, plc is the leading in-store brand for consumer wellness and self-care products. The company endured several years of declining earnings due to what we believe was poor capital allocation by its previous management team, which chased growth through acquisitions outside of Perrigo's core business. Our investment in Perrigo was inspired by a new management team that committed to pursuing realistic, steady growth rates within the core business, and the company delivering improved profitability and returns on capital. The stock underperformed during the quarter as earnings were guided to the low end of the previously given range due to sales and margin headwinds in their recovering infant formula business. While the fundamental difference in the guide down was small, investor patience has worn thin after years of delayed improvement. We continue to hold Perrigo in the portfolio. :contentReference[oaicite:6]{index=6} BSD Analysis: PRGO's turnaround hinges on core self-care focus, margin rebuild, and better capital allocation. Infant formula normalization and cost efficiencies should lift EPS. Valuation remains undemanding versus staples peers; improving ROIC is the re-rating lever.” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.